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Resistance index through EBUS in enlarged mediastinal lymph 
nodes - a new technique to evaluate for malignant involvement
Herth, Felix J.1 Eberhardt, Ralf1 Muley, Thomas1 Krasnik, Mark2 Ernst, 
Armin3 
1 Thoraxklinik Heidelberg, Heidelberg, Germany 2 Dep. of Thoracic 
Surgery, Copenhagen, Denmark 3 BIDMC, Harvard Medical School, 
Boston, MA, USA 
Objective: The vascular resistive index (RI) is measured by Doppler 
ultrasound and can be correlating with certain disease states. In order 
to establish the range of RI in enlarged LN, a study of 100 patients was 
performed with EBUS-TBNA Duplex Doppler ultrasound.
Methods: Consecutive patients with enlarged mediastinal LN were 
examined. 100 patients who had RI determined were included. All 
patients underwent surgical lymph node sampling to establish the rela-
tionship between histology (malignant or non- malignant) and RI.
Results: 152 pts were examined to include 100 in whom we were able 
to measure RI (54 male, 46 female, mean age 49y.). In 52 we were not 
able to visiualise the vessel. The histology revealed malignancy in 70 
cases and the RI was signiﬁcantly higher in those than in patients with-
out malignancy. Using the Youden Index we calculated a RI of 0,69 as 
the cut- off point for best discrimination (sensitivity 91,4 %, speciﬁcity 
90 %, p< 0,001). The AUC was 0,965 with an excellent discriminatory 
power (95 % conﬁdence interval 0,931 to 0,998) 
Conclusion: These results suggest that an increased RI seems to be 
highly correlated with a malignant histology. Conversely, a benign 
biopsy result through EBUS TBNA with a low RI may allow to forgo 
further testing.
PD1-2-2 EUS and PET-CT in Lung Cancer Staging, Mon, 16:00 - 17:30
The role of whole-body FDG PET/CT, Tc 99m mdp bone 
scintigraphy, and serum alkaline phosphatase in detecting bone 
metastasis in patients with newly diagnosed lung cancer
Min, Joo-Won; Um, Sang-Won; Yim, Jae-Jun; Yoo, Chul-Gyu; Han, 
Sung Koo; Shim, Young-Soo; Kim, Young Whan 
Seoul National University Hospital, Seoul, Korea
Background: Bone scan and serum alkaline phosphatase concentration 
are used to detect bone metastasis in malignancy, although whole-body 
FDG PET/CT is being used increasingly.
Objectives: To compare the usefulness of whole-body FDG PET/CT, 
bone scan, and serum alkaline phosphatase in detecting bone metasta-
ses in patients with newly diagnosed primary lung cancer.
Methods: The electronic medical record database at our institution 
was queried to identify all patients with a new diagnosis of lung cancer 
between January 2004 and December 2005, who had a PET/CT, bone 
scan, and check of serum alkaline phosphatase concentration before 
treatment. We retrospectively reviewed all patients’ medical records 
and radiological reports, and conﬁrmed bone metastases by considering 
all available clinical information.
Results: One hundred eighty-two patients met the inclusion criteria. 
Bone metastases were conﬁrmed in 30 patients. The average inter-
val between PET/CT and bone scan was 8.5 ± 14.0 days. Forty-nine 
patients had stage 4 nonsmall cell lung cancer, and seven patients had 
extensive stage small cell lung cancer.
The sensitivities, speciﬁcities and accuracies of PET/CT, bone scan, 
and serum alkaline phosphatase concentration were noted in following 
table. The kappa statistics were calculated for the three modalities. The 
kappa value was 0.19 between PET/CT and bone scan, 0.03 between 
bone scan and serum ALP concentration, and 0.15 between serum 
ALP concentration and PET/CT. The low kappa values suggested poor 
agreement between the three modalities.
Conﬁrmation of bone metastasis
Conﬁrmation criteria Number of patients
Progressing bone lesion on follow-up scan (PET/CT or bone scan) 2
Conﬁrmed bone metastasis by simple radiography, CT, or MRI 22
Positive initial ﬁndings on both bone scan and PET/CT in the same bone lesion 
with symptoms 5
Histological conﬁrmation 1
Total 30
Sensitivity, speciﬁcity, and accuracy of PET/CT, bone scan,  
and serum ALP concentration
 Sensitivity Speciﬁcity Accuracy
Positive 
predictive 
value
Negative 
predictive 
value
FDG PET/CT 93.3% (28/30)
94.1% 
(143/152)
93.4% 
(171/182)
75.7% 
(28/37)
98.6% 
(143/145)
Bone scan 93.3% (28/30)
44.1% 
(67/152)
52.2% 
(95/182)
24.7% 
(28/113)
97.1% 
(67/69)
Serum ALP 26.7% (8/30) 94.1% (143/152)
83.0% 
(151/182) 47.1% (8/17)
86.7% 
(143/165)
Serum ALP + 
bone scan 26.7% (8/30)
97.3% 
(148/152)
85.7% 
(156/182) 66.7% (8/12)
87.1% 
(148/170)
 
Conclusions: FDG PET/CT and bone scan had similar sensitivity, but 
PET/CT had better speciﬁcity and accuracy than bone scan. PET/CT is 
more useful than bone scan for evaluating bone metastasis. However, in 
the advanced stage, because of its high speciﬁcity, bone scan comple-
mented with serum alkaline phosphatase is a cost-effective modality to 
avoid having to use PET/CT.
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Trans-esophageal EUS-guided fine-needle aspiration and core 
biopsy for undetermined mediastinal lesions
Choi, Chang-Min1 Song, Ho June2 Seo, Dong Wan2 Shim, Tae Sun1 
Kim, Woo Sung1 
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Medicine, Asan Medical Center, College of Medicine, University of 
Ulsan, Seoul, Korea 
Background and Aims: EUS-guided ﬁne-needle aspiration & core 
biopsy (EUS-FNA/CB) is a minimally invasive diagnostic modality 
for tissue conﬁrmation of gastrointestinal or adjacent lesions. It would 
be more valuable in tuberculosis-prevalent settings because in which 
lymph nodes often enlarge reactively. This study is aimed to evaluate 
the diagnostic yields of EUS-FNA/CB for undetermined mediastinal 
lesions, and further to assess its clinical value in patients with present 
or prior history of pulmonary tuberculosis. 
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Methods: Thirty-nine consecutive cases consulted for undetermined 
mediastinal lesions from July 2005 to August 2006 were enrolled. 
Linear echoendoscope and 22-gauge aspiration or 19-gauge Trucut 
needles were used. Final diagnoses were determined by EUS-FNA/CB 
cytology, biospy, surgical pathology, or clinical follow-ups.
Results: Indications for EUS-FNA/CB were for histologic sampling 
in 24 cases (including suspected lung cancer, 9; other malignancy, 6; 
granulomatous disease, 3; unknown lesion, 6) and for stage conﬁrma-
tion of 15 proven malignancies (lung cancer, 11; extra-pulmonary 
malignancy, 4). FNA/CB was performed by mean number of 3.6 passes 
with four minimal complications (fever, 3; pain, 1). Malignant pathol-
ogy was obtained in 12 cases (primary lung cancer, 7; unknown origin, 
4; lymphoma, 1), and nine were deﬁned as benign lesions (tuberculo-
sis, 3; sarcoidosis, 1; reactive lymph node, 4; inconclusive bacterial 
infection, 1). In staging of 16 patients with proven malignancy (nodal 
staging of lung cancer, 11; metastasis of extra-pulmonary malignancy, 
4; recurrence of breast cancer, 1), 14 cases were diagnostic (metastatic, 
7; reactive, 7). Only four specimens (10.3%) were inadequate. Eleven 
of 39 patients (28.2%) had history of tuberculosis (prior pulmonary 
history, 7; present clinical impression, 4). Of the seven, six underwent 
FNA/CB for nodal staging of lung cancer and proved to be diagnostic 
(metastatic, 2; reactive, 4). The diagnostic accuracy of EUS-FNA/CB 
was as follows: overall, 87.2% (34/39); malignancy-related, 92.9% 
(26/28); lung cancer-related, 88.9% (16/18); tuberculosis-related, 
90.9% (10/11). 
Conclusions: EUS-FNA/CB is an accurate diagnostic modality in 
tissue conﬁrmation of undetermined mediastinal lesions. In addition, 
it should be recognized as an indispensable procedure to deﬁne benign 
reactive mediastinal lymph nodes that are commonly encountered in 
highly prevalent area of pulmonary tuberculosis.
PD1-2-4 EUS and PET-CT in Lung Cancer Staging, Mon, 16:00 - 17:30
FDG-PET Imaging for Staging Early Intraluminal Squamous Cell 
Cancers
Lee, Pyng1 Comans, Emile F.2 Hoekstra, Otto S.2 Sutedja, Tom G.3 
1 Singapore General Hospital, Singapore, 2 Dept of Nuclear Medicine, 
VUMC, Amsterdam, The Netherlands 3 Dept of Pulmonary Diseases, 
VUMC, Amsterdam, The Netherlands 
Introduction: Fluoro-deoxyglucose positron emission tomography 
(PET) has a diagnostic and prognostic value in staging and surveillance 
of non-small cell lung cancer. Several studies have also demonstrated 
its potential in assessing biologic aggressiveness of the primary tumor.
Aims: To evaluate the role of PET for early intraluminal squamous cell 
cancer (ISCC). 
Methods: Patients with early ISCC detected by autoﬂuorescence bron-
choscopy (AF) and conﬁned within the airway wall deﬁned initially by 
high resolution CT at 1 mm (subsequently by multidetector CT at 0.75 
mm slices) underwent PET imaging. 
Results: Sixty current and former smokers (47 males) with median 
age 68 years (range, 62-74) were consecutively entered in this study. 
Twenty four patients had visible tumor margins measuring ≤ 1cm2 
whilst 36 had margins extending beyond the visibility of AFB. PET 
was positive in 23 patients (38%): 7 (7/24, 39%) patients with margin-
visible tumors and 17 (16/36, 44%) with margin-invisible tumors. Nine 
patients underwent surgery for margin-invisible cancers of which 6 
were PET positive. However, 4 of the resected PET positive cancers 
were found to be severe dysplasia in 3 and mild dysplasia in 1. Medi-
astinal staging of the 9 patients who underwent surgery revealed 1 true 
PET positive N1 and 5 true negative N0. Two patients had false PET 
positive lymph nodes which were adjacent to the primary tumors and 1 
had false negative N1 that measured 6mm on CT. No distant metastasis 
was observed. The remaining patients were surgically unﬁt and were 
treated with bronchoscopic therapy. Median follow up was 40 months 
(range, 21-72), 41 patients were alive and 19 deceased. Lung cancer 
related mortality was 13%. PET positive cancers did not result in worse 
survival difference, p= 0.46 (Fig 1). 
Conclusion: Our preliminary results indicated that PET was not useful 
for the evaluation and prognostication of patients with early ISCC con-
ﬁned within the bronchial wall. In fact, false-positive PET results led to 
unnecessary surgery in 4 patients. 
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Mediastinal Lymph Node Staging in lung cancer by integrated 
FDG-PET/CT based SUV value calculation. A prospective series
Tournoy, Kurt G.1 Maddens, Soﬁe2 Gosselin, Robert2 Kelles, Mieke2 
Van Maele, Georges2 Van Meerbeeck, Jan2 
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Background: Non-small cell lung cancer (NSCLC) staging directs 
treatment choice and inﬂuences prognosis. The diagnostic performance 
of conventional FDG-PET scan in lymph node (LN) staging is too 
low to avoid invasive nodal staging. It remains unknown whether the 
diagnostic performance of integrated FDG-PET/CT for LN staging, and 
the calculation of Standard Uptake Values (SUV) could make invasive 
staging redundant.
Methods: We prospectively investigated the mediastinal and/or hilar 
LN in patients with proven NSCLC with an integrated FDG-PET/CT. 
Pathologic conﬁrmation of all suspicious LN was obtained. The diag-
nostic performance of the FDG-PET/CT fusion images and of the SUV 
calculation was measured to the stage the intrathoracic LN.
Results: 105 intrathoracic LN stations from 52 patients with NSCLC 
were characterized. The prevalence of LN malignancy was 36%. The 
sensitivity of integrated FDG-PET/CT to detect malignant LN was 84% 
and its speciﬁcity was 85% (Positive likelihood ratio 5.64, Negative 
likelihood ratio 0.19). SUVMAX, SUVMEAN and the ratio of SUV-
MAX/SUVLIVER values were all signiﬁcantly higher in malignant 
than in benign LN. The ROC area did not differ between these three 
